VMAT2 Inhibitors for the Treatment of Tardive Dyskinesia

References

• American Psychiatric Association (APA). (2013). Diagnostic and Statistical Manual of Mental Disorders, (5th ed.). American Psychiatric Association Publishing. https://doi.org/https://doi.org/10.1176/appi.books.9780890425596.MedicationInduced
   Google Scholar
• Anderson, K. E., Stamler, D., Davis, M. D., Factor, S. A., Hauser, R. A., Isojärvi, J., Jarskog, L. F., Jimenez-Shahed, J., Kumar, R., McEvoy, J. P., Ochudlo, S., Ondo, W. G., & Fernandez, H. H. (2017). Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): A double-blind, randomised, placebo-controlled, phase 3 trial. The Lancet Psychiatry, 4(8), 595–604. https://doi.org/https://doi.org/10.1016/S2215-0366(17)30236-5
   PubMed Web of Science ®Google Scholar
• Ascher-Svanum, H., Zhu, B., Faries, D., Peng, X., Kinon, B. J., & Tohen, M. (2008). Tardive dyskinesia and the 3-year course of schizophrenia: Results from a large, prospective, naturalistic study. The Journal of Clinical Psychiatry, 69(10), 1580–1588. http://www.ncbi.nlm.nih.gov/pubmed/19192441
   PubMed Web of Science ®Google Scholar
• Austedo [Prescribing Information]. (2020). Teva Pharmaceutical Industries, USA, Inc. https://www.austedo.com/globalassets/austedo/prescribing-information.pdf
   Google Scholar
• Bhidayasiri, R., Fahn, S., Weiner, W. J., Gronseth, G. S., Sullivan, K. L., & Zesiewicz, T. A, American Academy of Neurology (2013). Evidence-based guideline: Treatment of tardive syndromes: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology, 81(5), 463–469. https://doi.org/https://doi.org/10.1212/WNL.0b013e31829d86b6
   PubMed Web of Science ®Google Scholar
• Bhidayasiri, R., Jitkritsadakul, O., Friedman, J. H., & Fahn, S. (2018). Updating the recommendations for treatment of tardive syndromes: A systematic review of new evidence and practical treatment algorithm. Journal of the Neurological Sciences, 389, 67–75. https://doi.org/https://doi.org/10.1016/j.jns.2018.02.010
   PubMed Web of Science ®Google Scholar
• Carbon, M., Hsieh, C. H., Kane, J. M., & Correll, C. U. (2017). Tardive dyskinesia prevalence in the period of second-generation antipsychotic use: A meta-analysis. The Journal of Clinical Psychiatry, 78(3), e264–e278. https://doi.org/https://doi.org/10.4088/JCP.16r10832
   PubMed Web of Science ®Google Scholar
• Caroff, S. N., Aggarwal, S., & Yonan, C. (2018a). Treatment of tardive dyskinesia with tetrabenazine or valbenazine: A systematic review. Journal of Comparative Effectiveness Research, 7(2), 135–148. https://doi.org/https://doi.org/10.2217/cer-2017-0065
   PubMed Web of Science ®Google Scholar
• Caroff, S. N., & Campbell, E. C. (2016). Drug-induced extrapyramidal syndromes: Implications for contemporary practice. The Psychiatric Clinics of North America, 39(3), 391–411. https://doi.org/https://doi.org/10.1016/j.psc.2016.04.003
   PubMed Web of Science ®Google Scholar
• Caroff, S. N., Citrome, L., Meyer, J., Sajatovic, M., Goldberg, J. F., Jain, R., Lundt, L., Lindenmayer, J. P., McEvoy, J. P., McIntyre, R. S., Tohen, M., & Ketter, T. A. (2020a). A modified delphi consensus study of the screening, diagnosis, and treatment of tardive dyskinesia. Journal of Clinical Psychiatry, 81(2), 19cs12983 https://doi.org/https://doi.org/10.4088/JCP.19cs12983
   PubMed Web of Science ®Google Scholar
• Caroff, S. N., Ungvari, G. S., & Cunningham-Owens, D. G. (2018b). Historical perspectives on tardive dyskinesia. Journal of the Neurological Sciences, 389, 4–9. https://doi.org/https://doi.org/10.1016/j.jns.2018.02.015
   PubMed Web of Science ®Google Scholar
• Caroff, S. N., Yeomans, K., Lenderking, W. R., Cutler, A. J., Tanner, C. M., Shalhoub, H., Page, V., Chen, J., Franey, E., & Yonan, C. (2020b). RE-KINECT: A prospective study of the presence and healthcare burden of tardive dyskinesia in clinical practice settings. Journal of Clinical Psychopharmacology, 40(3), 259–268. https://doi.org/https://doi.org/10.1097/JCP.0000000000001201
   PubMed Web of Science ®Google Scholar
• Carton, L., Cottencin, O., Lapeyre-Mestre, M., Geoffroy, P. A., Favre, J., Simon, N., Bordet, R., & Rolland, B. (2015). Off-label prescribing of antipsychotics in adults, children and elderly individuals: A systematic review of recent prescription trends. Current Pharmaceutical Design, 21(23), 3280–3297. https://doi.org/https://doi.org/10.2174/1381612821666150619092903
   PubMed Web of Science ®Google Scholar
• Casey, D. E., & Rabins, P. (1978). Tardive dyskinesia as a life-threatening illness. American Journal of Psychiatry, 135(4), 486–488. https://doi.org/https://doi.org/10.1176/ajp.135.4.486
   PubMed Web of Science ®Google Scholar
• Cutler, A. J., Caroff, S. N., Tanner, C. M., Shalhoub, H., Lenderking, W. R., Wilcox, T., Franey, E., & Yonan, C. (2020). Impact of possible tardive dyskinesia on caregivers: Results from a prospective real-world screening study (RE-KINECT). Presented virtually at the 18th Annual Conference of the American Academy of Developmental Medicine and Dentristry, June 5–7.
   Google Scholar
• De Hert, M., Detraux, J., van Winkel, R., Yu, W., & Correll, C. U. (2011). Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nature Reviews. Endocrinology, 8(2), 114–126. https://doi.org/https://doi.org/10.1038/nrendo.2011.156
   PubMed Web of Science ®Google Scholar
• Definition of classes of evidence (CoE) and overall strength of evidence (SoE). (2014). Evidence-Based Spine-Care Journal, 5(1), 71. https://doi.org/https://doi.org/10.1055/s-0034-1373841
   PubMedGoogle Scholar
• Factor, S. A., Burkhard, P. R., Caroff, S., Friedman, J. H., Marras, C., Tinazzi, M., & Comella, C. L. (2019). Recent developments in drug-induced movement disorders: A mixed picture. The Lancet Neurology, 18(9), 880–890. https://doi.org/https://doi.org/10.1016/S1474-4422(19)30152-8
   PubMed Web of Science ®Google Scholar
• Factor, S. A., Remington, G., Comella, C. L., Correll, C. U., Burke, J., Jimenez, R., Liang, G. S., & O’Brien, C. F. (2017). The effects of valbenazine in participants with tardive dyskinesia: Results of the 1-Year KINECT 3 extension study. The Journal of Clinical Psychiatry, 78(9), 1344–1350. https://doi.org/https://doi.org/10.4088/JCP.17m11777
   PubMed Web of Science ®Google Scholar
• Fernandez, H. H., Factor, S. A., Hauser, R. A., Jimenez-Shahed, J., Ondo, W. G., Jarskog, L. F., Meltzer, H. Y., Woods, S. W., Bega, D., LeDoux, M. S., Shprecher, D. R., Davis, C., Davis, M. D., Stamler, D., & Anderson, K. E. (2017). Randomized controlled trial of deutetrabenazine for tardive dyskinesia: The ARM-TD study. Neurology, 88(21), 2003–2010. https://doi.org/https://doi.org/10.1212/WNL.0000000000003960
   PubMed Web of Science ®Google Scholar
• Fernandez, H. H., Stamler, D., Davis, M. D., Factor, S. A., Hauser, R. A., Jimenez-Shahed, J., Ondo, W. G., Jarskog, L. F., Woods, S. W., Bega, D., LeDoux, M. S., Shprecher, D. R., & Anderson, K. E. (2019). Long-term safety and efficacy of deutetrabenazine for the treatment of tardive dyskinesia. Journal of Neurology, Neurosurgery, and Psychiatry, 90(12), 1317–1323. https://doi.org/https://doi.org/10.1136/jnnp-2018-319918
   PubMedGoogle Scholar
• Frei, K., Truong, D. D., Fahn, S., Jankovic, J., & Hauser, R. A. (2018). The nosology of tardive syndromes. Journal of the Neurological Sciences, 389, 10–16. https://doi.org/https://doi.org/10.1016/j.jns.2018.02.008
   PubMed Web of Science ®Google Scholar
• Gardos, G., Cole, J. O., & Tarsy, D. (1978). Withdrawal syndromes associated with antipsychotic drugs. American Journal of Psychiatry, 135(11), 1321–1324. https://doi.org/https://doi.org/10.1176/ajp.135.11.1321
   PubMed Web of Science ®Google Scholar
• Grigoriadis, D. E., Smith, E., Hoare, S. R., Madan, A., & Bozigian, H. (2017). Pharmacologic characterization of valbenazine (NBI-98854) and its metabolites. Journal of Pharmacology and Experimental Therapeutics, 361(3), 454–461. https://doi.org/https://doi.org/10.1124/jpet.116.239160
   PubMed Web of Science ®Google Scholar
• Guy, W. (1976). ECDEU Assessment Manual for Psychopharmacology: Revised (DHEW publication number ADM 76-338). U.S. Dept. of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs.
   Google Scholar
• Harriott, N. D., Williams, J. P., Smith, E. B., Bozigian, H. P., & Grigoriadis, D. E. (2018). VMAT2 inhibitors and the path to ingrezza (valbenazine). Progress in Medicinal Chemistry, 57(1), 87–111. https://doi.org/https://doi.org/10.1016/bs.pmch.2017.12.002
   PubMedGoogle Scholar
• Hauser, R. A., Factor, S. A., Marder, S. R., Knesevich, M. A., Ramirez, P. M., Jimenez, R., Burke, J., Liang, G. S., & O’Brien, C. F. (2017). KINECT 3: A phase 3 randomized, double-blind, placebo-controlled trial of valbenazine for tardive dyskinesia. American Journal of Psychiatry, 174(5), 476–484. https://doi.org/https://doi.org/10.1176/appi.ajp.2017.16091037
   PubMed Web of Science ®Google Scholar
• Hauser, R. A., Meyer, J. M., Factor, S. A., Comella, C. L., Tanner, C. M., Xavier, R. M., Caroff, S. N., & Lundt, L. (2020). Differentiating tardive dyskinesia: A video-based review of antipsychotic-induced movement disorders in clinical practice. CNS Spectrums, 1–10. https://doi.org/https://doi.org/10.1017/S109285292000200X
   Web of Science ®Google Scholar
• Ingrezza [Prescribing Information]. (2021). Neurocrine biosciences. https://www.neurocrine.com/assets/INGREZZA-full-Prescribing-Information.pdf
   Google Scholar
• Jain, R., & Correll, C. U. (2018). Tardive dyskinesia: Recognition, patient assessment, and differential diagnosis. Journal of Clinical Psychiatry, 79(2), nu17034ah1c https://doi.org/https://doi.org/10.4088/JCP.nu17034ah1c
   Web of Science ®Google Scholar
• Jinnah, H. A., & Factor, S. A. (2015). Diagnosis and treatment of dystonia. Neurologic Clinics, 33(1), 77–100. https://doi.org/https://doi.org/10.1016/j.ncl.2014.09.002
   PubMed Web of Science ®Google Scholar
• Kane, J. M., Correll, C. U., Nierenberg, A. A., Caroff, S. N., & Sajatovic, M.; on behalf of the Tardive Dyskinesia Assessment Working Group. (2018). Revisiting the Abnormal Involuntary Movement Scale: Proceedings from the Tardive Dyskinesia Workshop. Journal of Clinical Psychiatry, 79(3), 17cs11959.
   PubMed Web of Science ®Google Scholar
• Keepers, G. A., Fochtmann, L. J., Anzia, J. M., Benjamin, S., Lyness, J. M., Mojtabai, R., Servis, M., Walaszek, A., Buckley, P., Lenzenweger, M. F., Young, A. S., Degenhardt, A., & Hong, S. H. (2020). The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia. The American Journal of Psychiatry, 177(9), 868–872. https://doi.org/https://doi.org/10.1176/appi.ajp.2020.177901
   PubMed Web of Science ®Google Scholar
• Lindenmayer, J. P., Verghese, C., Marder, S. R., Burke, J., Jimenez, R., Siegert, S., Liang, G. S., & O’Brien, C. F. (2020). A long-term, open-label study of valbenazine for tardive dyskinesia. CNS Spectrums, 1–9. https://doi.org/https://doi.org/10.1017/S109285292000108X
   Web of Science ®Google Scholar
• Loy, J. H., Merry, S. N., Hetrick, S. E., & Stasiak, K. (2017). Atypical antipsychotics for disruptive behaviour disorders in children and youths. Cochrane Database of Systematic Reviews, 8(8), CD008559. https://doi.org/https://doi.org/10.1002/14651858.CD008559.pub3
   PubMed Web of Science ®Google Scholar
• Lundt, L., Franey, E., Shah, C., & Yonan, C. (2020). Chart extraction/clinician survey shows symptom impact and favorable treatment outcomes with VMAT2 inhibitors in patients with tardive dyskinesia [poster]. [Paper presentation]. Presented virtually at the annual meeting of the American Society of Clinical Psychopharmacology, May 29–30.
   Google Scholar
• Lunsky, Y., Khuu, W., Tadrous, M., Vigod, S., Cobigo, V., & Gomes, T. (2018). Antipsychotic use with and without comorbid psychiatric diagnosis among adults with intellectual and developmental disabilities. Canadian Journal of Psychiatry. Revue Canadienne de Psychiatrie, 63(6), 361–369. https://doi.org/https://doi.org/10.1177/0706743717727240
   PubMed Web of Science ®Google Scholar
• Luo, R., Bozigian, H., Jimenez, R., Loewen, G., & O’Brien, C. F. (2017). Single dose and repeat once-daily dose safety, tolerability and pharmacokinetics of valbenazine in healthy male subjects. Psychopharmacology Bulletin, 47(3), 44–52. https://www.ncbi.nlm.nih.gov/pubmed/28839339
   PubMedGoogle Scholar
• Macpherson, R., & Collis, R. (1992). Tardive dyskinesia. Patients’ lack of awareness of movement disorder. The British Journal of Psychiatry: The Journal of Mental Science, 160, 110–112. https://www.cambridge.org/core/journals/the-british-journal-of-psychiatry/article/abs/tardive-dyskinesia/764D763230079313B4253947DEBEDFEE
   PubMed Web of Science ®Google Scholar
• Marder, S. R., Singer, C., Lindenmayer, J. P., Tanner, C. M., Comella, C. L., Verghese, C., Jimenez, R., Liang, G. S., Burke, J., & O’Brien, C. F. (2019). A phase 3, 1-year, open-label trial of valbenazine in adults with tardive dyskinesia. Journal of Clinical Psychopharmacology, 39(6), 620–627. https://doi.org/https://doi.org/10.1097/JCP.0000000000001111
   PubMed Web of Science ®Google Scholar
• O’Brien, C. F., Jimenez, R., Hauser, R. A., Factor, S. A., Burke, J., Mandri, D., & Castro-Gayol, J. C. (2015). NBI-98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: A randomized, double-blind, placebo-controlled study. Movement Disorders, 30(12), 1681–1687. https://doi.org/https://doi.org/10.1002/mds.26330
   PubMed Web of Science ®Google Scholar
• Pringsheim, T., Gardner, D., Addington, D., Martino, D., Morgante, F., Ricciardi, L., Poole, N., Remington, G., Edwards, M., Carson, A., & Barnes, T. R. E. (2018). The assessment and treatment of antipsychotic-induced akathisia. Canadian Journal of Psychiatry. Revue Canadienne de Psychiatrie, 63(11), 719–729. https://doi.org/https://doi.org/10.1177/0706743718760288
   PubMed Web of Science ®Google Scholar
• Samie, M. R., Dannenhoffer, M. A., & Rozek, S. (1987). Life-threatening tardive dyskinesia caused by metoclopramide. Movement Disorders: Official Journal of the Movement Disorder Society, 2(2), 125–129. https://doi.org/https://doi.org/10.1002/mds.870020207
   PubMedGoogle Scholar
• Savitt, D., & Jankovic, J. (2018). Tardive syndromes. Journal of the Neurological Sciences, 389, 35–42. https://doi.org/https://doi.org/10.1016/j.jns.2018.02.005
   PubMed Web of Science ®Google Scholar
• Schneider, F., Bradbury, M., Baillie, T. A., Stamler, D., Hellriegel, E., Cox, D. S., Loupe, P. S., Savola, J. M., & Rabinovich-Guilatt, L. (2020). Pharmacokinetic and metabolic profile of deutetrabenazine (TEV-50717) compared with tetrabenazine in healthy volunteers. Clinical and Translational Science, 13(4), 707–717. https://doi.org/https://doi.org/10.1111/cts.12754
   PubMed Web of Science ®Google Scholar
• Skor, H., Smith, E. B., Loewen, G., O’Brien, C. F., Grigoriadis, D. E., & Bozigian, H. (2017). Differences in dihydrotetrabenazine isomer concentrations following administration of tetrabenazine and valbenazine. Drugs in R&D, 17(3), 449–459. https://doi.org/https://doi.org/10.1007/s40268-017-0202-z
   PubMed Web of Science ®Google Scholar
• Stacy, M., Sajatovic, M., Kane, J. M., Cutler, A. J., Liang, G. S., O’Brien, C. F., & Correll, C. U. (2019). Abnormal involuntary movement scale in tardive dyskinesia: Minimal clinically important difference. Movement Disorders, 34(8), 1203–1209. https://doi.org/https://doi.org/10.1002/mds.27769
   PubMed Web of Science ®Google Scholar
• Stahl, S. M. (2018). Comparing pharmacologic mechanism of action for the vesicular monoamine transporter 2 (VMAT2) inhibitors valbenazine and deutetrabenazine in treating tardive dyskinesia: Does one have advantages over the other? CNS Spectrums, 23(4), 239–247. https://doi.org/https://doi.org/10.1017/S1092852918001219
   PubMed Web of Science ®Google Scholar
• Teo, J. T., Edwards, M. J., & Bhatia, K. (2012). Tardive dyskinesia is caused by maladaptive synaptic plasticity: A hypothesis. Movement Disorders: Official Journal of the Movement Disorder Society, 27(10), 1205–1215. https://doi.org/https://doi.org/10.1002/mds.25107
   PubMed Web of Science ®Google Scholar
• Vinuela, A., & Kang, U. J. (2014). Reversibility of tardive dyskinesia syndrome. Tremor and Other Hyperkinetic Movements (New York, N.Y.), 4(0), 282. https://doi.org/https://doi.org/10.7916/D86Q1VXZ
   PubMedGoogle Scholar
• Waln, O., & Jankovic, J. (2013). An update on tardive dyskinesia: From phenomenology to treatment. Tremor and Other Hyperkinetic Movements (New York, N.Y.), 3, tre-03-161-4138-1. https://doi.org/https://doi.org/10.7916/D88P5Z71
   Google Scholar
• Ward, K. M., & Citrome, L. (2018). Antipsychotic-related movement disorders: Drug-induced parkinsonism vs. tardive dyskinesia-key differences in pathophysiology and clinical management. Neurology and Therapy, 7(2), 233–248. https://doi.org/https://doi.org/10.1007/s40120-018-0105-0
   PubMed Web of Science ®Google Scholar
• Xenazine [Prescribing Information]. (2019). Lundbeck. https://www.lundbeck.com/upload/us/files/pdf/Products/Xenazine_PI_US_EN.pdf
   Google Scholar
• Zadori, D., Veres, G., Szalardy, L., Klivenyi, P., & Vecsei, L. (2015). Drug-induced movement disorders. Expert Opinion on Drug Safety, 14(6), 877–890. https://doi.org/https://doi.org/10.1517/14740338.2015.1032244
   PubMed Web of Science ®Google Scholar
• Zutshi, D., Cloud, L. J., & Factor, S. A. (2014). Tardive syndromes are rarely reversible after discontinuing dopamine receptor blocking agents: Experience from a university-based movement disorder clinic. Tremor and Other Hyperkinetic Movements (New York, N.Y.), 4, 266. https://doi.org/https://doi.org/10.7916/d8ms3r8c
   PubMedGoogle Scholar